| MARYLAND |
Location: Annapolis
Anne
Arundeel Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Elizabeth F. Egan
443-481-5811
eegan@aahs.org
Back
to Top |
Location: Baltimore
John
Hopkins Hospital
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,
3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Ann Morrison
410-614-4605
amorris7@jhmi.edu
Back
to Top |
Location: Baltimore
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Paul Rosenburg
877-379-3718
Back
to Top |
Location: Easton
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
AllanBeth Parker-O'Brien, LCSW-C
410-820-4005
Back to Top |
Location: Glen Burnie
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Lawrence Adler
877-379-3718
Back
to Top |
Location: Oxon Hill
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen Ong
877-379-3718
Back
to Top |
Location: Rockville
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David Denicoff
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: Brain Study of Patients with Frontal
Lobe Dementia and Parkinsonian Disorders-
National Institute of Neurological Disorders and
Stroke proposes to continue its cross-sectional and
longitudinal studies of cerebral metabolism in frontal
lob dementias and atypical basal ganglia disorders.
These studies include repeated assessments of
neuropsychological and brain anatomical and metabolic
function in subjects with these important and possibly
related brain disorders.
Enrollment Status: Recruiting
Study Dates: Start: January
1981
Condition: Alzheimer's disease,
Dementia, Down's syndrome
Age
Eligibility: 18 and above
Gender
Eligibility: Both
Enrollment
Goal: 675
Clinical
Identifier: NCT00001178
Study
Phase: N/A
Study Type: Observational
Sponsor: National Institute of
Neurological Disorders and Stroke (NINDS)
Contact Information:
Patient Recruitment and Public Liaison
Office
800-411-1222
Back
to Top |
Location: Call for details
Trial Title and Description: MRI of Alzheimer's Disease: Imaging
Amyloid Plaques in Persons With and Without Memory
Problems-
This study will investigate the possibility of
detecting early signs of Alzheimer's disease using
magnetic resonance imaging (MRI). If plaques can be
imaged by MRI, the procedure could be used in clinical
trials and may also help in the clinical diagnosis of
patients.
Enrollment Status: Recruiting
Study Dates: Start: December
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 40
Clinical Identifier: NCT00413621
Study Phase: N/A
Study Type: Observational
Sponsor: National Institute of
Neurological Disorders and Stroke (NINDS)
Contact Information:
Andrea Nelson
anelson18@jhmi.edu
Back
to Top |
Location: Call for details
Trial Title and Description: PET Scanning [11C] MeS-IMPY to
Measure Amyloid in Brain-
This study will use positron emission tomography
(PET) to measure a protein called amyloid in the
brains of healthy volunteers and people with
Alzheimer's disease. The tracer used in this study is
a research drug called [11C]
MeS-IMPY.
Enrollment Status: Recruiting
Study Dates: Start: December
2006
Condition: Alzheimer's disease,
Neurodegenerative disease, Dementia
Age
Eligibility: Healthy subjects: 18-80
Alzheimer's diseases: 50-80
Gender
Eligibility: Both
Enrollment
Goal: 15
Clinical
Identifier: NCT00407576
Study
Phase: N/A
Study Type: Observational
Sponsor: National Institute of
Mental Health
Contact Information:
Patient Recruitment and Public Liaison
Office
800-411-1222
Back
to Top |
| MASSACHUSETTS |
Location: Boston
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Martha Vander Vliet, RN
617-732-8383
Back to Top |
Location: Boston
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Sumati Raghavan
617-414-1079
Back to Top |
Location: Burlington
Lahey Clinic, Inc.
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Junius Beebe
781-744-5601
Junius.O.Beebe@lahey.org
Back to Top |
Location: Pittsffield
Berkshire
Hematologgy Oncology/ Bershire Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Gloria F. Gero
413-496-8205
Back
to Top |
Location: Call for details
Trial Title and Description: Home Safety Clinical Trial-
The purpose of this study is to test the
effectiveness of a new multimodal educational
intervention to improve home safety for persons with
dementia of the Alzheimer's type and their home
caregivers.
Enrollment Status: Not yet
recruiting
Study Dates: Start: June 2007
Expected Completion: August 2009
Condition: Alzheimer's disease,
Dementia
Age Eligibility: 40 and
above
Gender Eligibility: Both
Enrollment Goal: 320
Clinical Identifier: NCT00459355
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Department of Veterans
Affairs
Contact Information:
Kathy J. Horvath
781-687-2006
kathy.horvath@med.va.gov
Back
to Top |
Location: Call for details
Trial Title and Description: Open-Label Extension Assessing Long
Term Safety of Rosiglitazone In Subjects with Mild To
Moderate Alzheimer's Disease-
This is an open-label extension to study 49653/461,
to assess the long-term safety of rosiglitazone
(extended release tablets) in subjects with mild to
moderate Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: February
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase
2
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
877-379-3718
Back
to Top |
Location: Call for
details
Trial Title and Description: REVEAL III: Risk Evaluation and
Education for Alzheimer's Disease-
The purpose of this study is to provide healthy
adults with genetic testing and information about
their chances of developing Alzheimer's
disease
Enrollment Status: Recruiting
Study Dates: Start: March 2007
Expected Completion: March 2010
Condition: Alzheimer's
disease
Age Eligibility: 18-85
Gender Eligibility: Both
Enrollment Goal: 280
Clinical Identifier: NCT00462917
Study Phase: N/A
Study Type: Observational
Sponsor: National Human Genome
Research Institute (NHGRI)
Contact Information:
Susan Hiraki
617-638-5355
shiraki@bu.edu
Back
to Top |
| MICHIGAN |
Location: Adrian
Bixby Oncology
Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Michael Uscio
419-843-6147
Back
to Top |
Location: Ann Arbor
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Ellen Near
734-973-9700
Back to Top |
Location: Detroit
Henry Ford
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Teresa Kay
313-916-3721
Back
to Top |
Location: Grand Rapids
Grand
Rapids Clinical Oncology Program CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Connie M. Szczepanek
616-391-1230
Back
to Top |
Location: Grand Rapids
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Herman Sullivan
877-379-3718
Back
to Top |
Location: Kalamazoo
Bronson Lakeview Psychiatry
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Gail Massey
269-341-8774
masseyg@bronsonhg.org
For more information, visit www.gapstudy.com
Back to Top
|
Location: Monroe
Monroe
Clinic
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Debbie Osemtoski
734-242-8585
Back
to Top |
Location: Pontiac
St. Joseph
Mercy Oakland
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Liz A. Bowie
248-858-6215
Back
to Top |
Location: Traverse City
Munson
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Pamela J. Bergman
231-935-6300
Back
to Top |
Location: Call for details
Trial Title and Description: Open-Label Extension Assessing Long
Term Safety of Rosiglitazone In Subjects with Mild To
Moderate Alzheimer's Disease-
This is an open-label extension to study 49653/461,
to assess the long-term safety of rosiglitazone
(extended release tablets) in subjects with mild to
moderate Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: February
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase
2
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: REVEAL III: Risk Evaluation and
Education for Alzheimer's Disease-
The purpose of this study is to provide healthy
adults with genetic testing and information about
their chances of developing Alzheimer's
disease
Enrollment Status: Recruiting
Study Dates: Start: March 2007
Expected Completion: March 2010
Condition: Alzheimer's
disease
Age Eligibility: 18-85
Gender Eligibility: Both
Enrollment Goal: 280
Clinical Identifier: NCT00462917
Study Phase: N/A
Study Type: Observational
Sponsor: National Human Genome
Research Institute (NHGRI)
Contact Information:
Susan Hiraki
617-638-5355
shiraki@bu.edu
Back
to Top |
| MINNESOTA |
Location: St. Paul
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Elizabeth Reeve
877-379-3718
Back
to Top |
Location: St. Paul
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Elizabeth Reeve
877-379-3718
Back
to Top |
| MISSISSIPPI |
Location: Mound Bayou
Delta
Health Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Not yet
recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu
Back
to Top |
| MISSOURI |
Location: Joplin
St. John's
Regional Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Rita Glaze
417-625-2949
Back
to Top |
Location: Springfield
Cancer
Research for the Ozarks
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Dean A. Matthews
417-269-4880
Back
to Top |
Location: Springfield
St.
John's Health System
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Gail Black
417-269-6513
Back
to Top |
Location: St. Louis
St. Louis University
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Susan Brown
314-977-4818
brownsa@slu.edu
Back to Top |
Location: Call for details
Trial Title and Description: Effect of Memantine on Functional
Communication in Patients with Alzheimer's Disease-
The objective of this study is to evaluate the
effect of memantine versus placebo on functional
communication in patients with Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2007
Condition: Alzheimer's
disease
Age Eligibility: 50 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00469456
Study Phase: Phase
4
Study Type: Interventional
Sponsor: Forest Laboratories
Contact Information:
Forest Professional
Affairs
800-678-1605
Back
to Top |
| MONTANA |
Location: Billings
Montana
Cancer Consortium CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Shirley A. Hall
406-259-2245
mcc@mcn.net
Back
to Top |
Location: Great Falls
Benefits
Health Care
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Laura K. Hodges
406-727-4584
Back
to Top |
| NEBRASKA |
Location: Kearney
Good
Samaritan Health Systems- Cancer Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Connie S. Wittman
308-865-7564
Back
to Top |
Location: Lincoln
Cancer
Resource Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kay L. Hoff
402-483-2827
khoff@lmef.org
Back
to Top |
Location: Omaha
University of Nebraska Medical Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Barbara Bayer
402-552-6005
blbayer@unmc.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: Omaha
Alegent Health
Bergan Mercy Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Catherine T. Basham
402-572-3223
Back
to Top |
Location: Omaha
Alegent Health
Immanuel Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Catherine T. Basham
402-572-3223
Back
to Top |
Location: Omaha
Missouri Valley
Cancer Cons CCOP/ Creighton University
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Penny Jo Anzures
402-280-5274
panzures@creighton.edu
Back
to Top |
| NEVADA |
Location: Las Vegas
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Michelle Sholar, C.R.C.
702-483-6026
Back to Top |
Location: Las Vegas
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
University of Nevada, School of Medicine
Lal Ramani
701-671-5096
www.KiokuStudy.com
Back to Top |
Location: Las Vegas
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Michael DePriest
877-379-3718
Back
to Top |
Location: Reno
Wasoe Medical
Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Jeannine Moore
775-982-5050
Back
to Top |
| NEW
HAMPSHIRE |
Location: Lebanon
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David Coffey
877-379-3718
Back
to Top |
| NEW
JERSEY |
Location: East Orange
VAMC New
Jersey Health Care System
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Karen Long
973-676-1000
Back
to Top |
Location: Kenilworth
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Justine Kent
877-379-3718
Back
to Top |
Location: Morristown
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stuart Fox
877-379-3718 ext. 33
Back
to Top |
Location: Mt. Arlington
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Janine Noyes, CRC
973-903-1818
Back to Top |
Location: Phillipsburg
Warren
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Bonnie L. Perrucci
908-859-6700
Back
to Top |
Location: Piscataway
University
of Medicine and Dentistry of New Jersey
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Julie Coleman
732-235-4907
colemanjs@umdnj.edu
Alison Grazioli
732-235-4907
alison.formica@qmail.com
William Reichman
Back
to Top |
Location: Princeton
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Benjamin Shechet
609-921-3555 ext 28
Back to Top |
Location: Princeton
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jeffrey Apter
877-379-3718
Back
to Top |
Location: Red Bank
Riverview
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Roxanna Valasa
732-530-2382
Back
to Top |
Location: Stratford
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen Scheinthal
877-379-3718
Back
to Top |
Location: Toms River
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Gerald Ferencz
877-379-3718
Back
to Top |
| NEW
YORK |
Location: Albany
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Susan M. Heckman, MS OT/L
518-262-0809
Back to Top |
Location: Albany
Stratton
Veterans Affairs Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Lori Megherian
518-626-6448
lori.megherian@med.va.gov
Back
to Top |
Location: Albany
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David Hart
877-379-3718
Back
to Top |
Location: Albany
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Richard Holub
877-379-3718
Back
to Top |
Location: Bronx
VAMC
Trial Title and Description: Development of NIC5-15 in the
Treatment of Alzheimer's Disease- Drug: D-Pinitol
The purpose of this study is to evaluate the safety
and efficacy of D-pinitol in the treatment of
Alzheimer's disease
Enrollment Status: Recruiting
Study Dates: Start: January 2007
Expected Completion: September 2009
Condition: Alzheimer's disease,
Dementia
Age Eligibility: N/A
Gender Eligibility: Both
Enrollment Goal: 10
Clinical Identifier: NCT00470418
Study Phase: Phase 1,
2
Study Type: Interventional
Sponsor: Department of Veterans
Affairs, National Center for Complementary and
Alternative Medicine
Contact Information:
Anthony Rotolo
718-584-9000, ext.
6007
anthony_rotolo@med.va.gov
Kathleen Van Dyk
718-584-9000, ext. 5199
Kathleen.vandyk@mssm.edu
Back
to Top |
Location: Brooklyn, NY
Trial Title and Description: A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50-90 Years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Brooklyn Medical Institute
Name: (Contact name has changed)
Phone: 718-339-7711
www.kiokustudy.com
Back to Top |
Location: Brooklyn, NY
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Brooklyn Medical Institute
Marina Mazur
718-339-7711
www.KiokuStudy.com
|
Location: Brooklyn
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Nicholas Vatakis
877-379-3718
Back
to Top |
Location: Cedarhurst
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Ewa Bosiacki
516-295-7230
Back to Top |
Location: Cooperstown
Bassett
Research Institute
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Anne-Marie Whitaker
607-547-3399
anne-marie.whitaker@bassett.org
Back
to Top |
Location: Glens Falls
Glens
Falls Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Barbara A. Sponzo
518-926-6700
Back
to Top |
Location: New York
Columbia University
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Ruth Tejeda
212-305-7661
rbt41@columbia.edu
Back to Top |
Location: New York
The Weill Cornell Memory Disorders Program (Cornell University)
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Kavita Shah
212-746-6581
kbs2001@med.cornell.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: New York
Mount Sinai School of Medical School
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
George Marzloff
212-241-1514
george.marzloff@mssm.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: New York
New York University Medical Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Erica Epstein
212-263-5708
erica.maya@med.nyu.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: New York
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Erica Maya
212-263-5708
Back to Top |
Location: New York
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Andrew Vigario
212-241-5692
Back to Top |
Location: New York
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Ram Shrivastava
877-379-3718
Back
to Top |
Location: New York
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Marcin Sadowski
877-379-3718
Back
to Top |
Location: Rochester
University of Rochester Medical Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Connie Brand
585-760-6585
connie_brand@urmc.rochester.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: Rochester
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Bonnie Goldstein
585-760-6561
Back to Top |
Location: Rochester
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
University of Rochester Medical Center
Kelly Stear
585-760-6550
www.KiokuStudy.com
Back to Top |
Location: Rochester
University
of Rochester
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,
3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Collen McCallum
585-760-6547
Collen_Mccallum@urmc.rochester.edu
Kimberly Martin
585-760-6548
Kimberly_Martin@urmc.rochester.edu
Back
to Top |
Location: Staten Island
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Daniela Pantea
718-351-3319
Back to Top |
Location: Staten Island
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Richmond Behavioral Associates
Adam Smith, Ph.D.
718-317-5522
www.KiokuStudy.com
Back to Top |
Location: Syracuse
Neurological
Care of CNY
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Seema Mirje
315-701-4554
smirje@neurocarecny.com
Smita Kittur
Back
to Top |
Location: Syracuse
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Smita Kittur
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: Couples Coping with Alzheimer's
Disease-
The purpose of this study is to test the efficacy
of a new couples counseling intervention for people
recently diagnosed with early Alzheimer's disease and
their spouses. The study hypothesis is that counseling
the couple shortly after the diagnosis, and while the
functional impact of the illness is still relatively
mild, will have a significant impact on their ability
to provide support for each
other.
Enrollment Status: Recruiting
Study Dates: Start: November 2004
Expected Completion: November 2007
Condition: Aging, Alzheimer's
disease, Dementia
Age Eligibility: 21-90
Gender Eligibility: Both
Enrollment Goal: 200
Clinical Identifier: NCT00438724
Study Phase: N/A
Study Type: Interventional
Sponsor: Alzheimer's
Association
Contact Information:
Cynthia Epstein
212-263-1056
cynthia.epstein@med.nyu.edu
Ursula Auclair
212-263-2245
ursulaauclair@med.nyu.edu
Back
to Top |
Location: Call for details
Trial Title and Description: A study of V950 in People with
Alzheimer's Disease-
The purpose of this study is to test the safety,
tolerability and immune response to an investigational
vaccine, V950.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00464334
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Merck
Contact Information:
Trial Manager
888-577-8839
Back
to Top |
Location: Call for details
Trial Title and Description: An Innovative Psychosocial
Intervention for Adult-Child Caregivers of Parents
With Alzheimer's-
The goal of this project is to test an intervention
designed to reduce the incidence and magnitude of the
negative effects, specifically stress, anxiety, and
depression, frequently experienced by adult children
who are caregivers of a parent with Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: September 2003
Expected Completion: April 2008
Condition: Alzheimer's
disease
Age Eligibility: 21-90
Gender Eligibility: Both
Enrollment Goal: 100
Clinical Identifier: NCT00409279
Study Phase: N/A
Study Type: Interventional
Sponsor: The Jacob and Valeria
Langeloth Foundation
Contact Information:
Olanta Barton
212-263-5710
olanta.barton@med.nyu.edu
Back
to Top |
Location: Call for details
Trial Title and Description: Biomarkers and Early Alzheimer's
Disease-
The main goal of this project is to use imaging and
biomarkers to identify cognitively normal elderly
people who are at increased risk for developing mild
cognitive impairment (MCI). MCI is the earliest
clinically detectable evidence for brain changes due
to Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: April 2003
Expected completion: March 2008
Condition: Alzheimer's
disease
Age Eligibility: 60-80
Gender Eligibility: Both
Enrollment Goal: 80
Clinical Identifier: NCT00094952
Study Phase: N/A
Study Type: Observational
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Kenneth E. Rich
212-263-7563
kenneth.rich@med.nyu.edu
Back
to Top |
Location: Call for details
Trial Title and Description: Predictors of Cognitive Decline in
Normal Aging-
This study will collect neuropsychological data,
magnetic resonance imaging (MRI), and cerebrospinal
fluid (CSF) from volunteer participants to measure the
relationship between changes in brain volume, CSF
levels, and memory performance.
Enrollment Status: Recruiting
Study Dates: Start: September 2003
Expected Completion: August 2008
Condition: Alzheimer's disease,
Dementia
Age Eligibility: 60-80
Gender Eligibility: Both
Enrollment Goal: 170
Clinical Identifier: NCT00094939
Study Phase: N/A
Study Type: Observational
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Kenneth E. Rich
212-263-7563
kenneth.rich@med.nyu.edu
Back
to Top |
| NORTH
CAROLINA |
Location: Durham
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Hala Husn
919-684-5929
Back to Top |
Location: Durham
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Duke University Medical Center
Debra Heydt
919-668-2843
www.KiokuStudy.com
Back to Top |
Location: Durham
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
James Burke
877-379-3718
Back
to Top |
Location: Raleigh
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Michael Brown
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: Comparison of 23 mg Donepezil
Sustained Release (SR) to 10 MG Donepezil Immediate
Release (IR) in patients-
The study consists of a double-blind, double-dummy,
parallel-group comparison of 23 mg donepezil sustained
release to the currently marketed formulation, 10 mg
donepezil immediate release, in patients with moderate
to severe Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2007
Condition: Alzheimer's
disease
Age Eligibility: 45-90
Gender Eligibility: Both
Enrollment Goal: 1,600
Clinical Identifier: NCT00478205
Study Phase: Phase
3
Study Type: Interventional
Sponsor: Eisai Medical Research
Inc.
Contact Information:
Eisai
Medical Services
1-888-422-4743
Back
to Top |
Location: Call for details
Trial Title and Description: Functional Brian Imaging of
Medication Treatment Response in Mild Alzheimer's
Disease Patients-
The purpose of this study is to determine whether
standard medications approved for Alzheimer’s disease
treatment differ in their action on brain functioning
and whether any observed brain activity differences
resulting from treatment are associated with
particular patterns of dementia improvement or reduced
decline.
Enrollment Status: Recruiting
Study Dates: Start: October 2006
Expected Completion: December 2007
Condition: Alzheimer's
disease
Age Eligibility: 40 and
above
Gender Eligibility: Both
Enrollment Goal: 36
Clinical Identifier: NCT00369603
Study Phase: Phase
4
Study Type: Interventional
Sponsor: Duke University,
Ortho-McNeil Neurologics, Inc.
Contact Information:
Michelle McCart
919-416-5387
misimons@duke.edu
Back
to Top |
Location: Call for details
Trial Title and Description: Open-Label Extension Assessing Long
Term Safety of Rosiglitazone In Subjects with Mild To
Moderate Alzheimer's Disease-
This is an open-label extension to study 49653/461,
to assess the long-term safety of rosiglitazone
(extended release tablets) in subjects with mild to
moderate Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: February
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase
2
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
877-379-3718
Back
to Top |
| OHIO |
Location: Beachwood
University Hospitals Case Medical Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Suee Foxhall
216-983-0796
suzanne.foxhall@uhhospitals.org
Back to Top
|
Location: Beachwood
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Elaine Ziol
216-464-6454
Back to Top
|
Location: Centerville
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact
Information:
Meenakshi
Patel
877-379-3718
Back
to Top |
Location: Cincinnati
Good
Samaritan Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Elyce P. Turba
513-872-2293
Back
to Top |
Location: Cleveland
Case
Western Reserve University
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Elaine Ziol
216-844-6328
elaine.ziol@case.edu
Nicole Trites Gunderson
216-844-6419
nicole.gunderson@case.edu
Alexander Auchus
Back
to Top |
Location: Cleveland
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Alan Lerner
877-379-3718
Robert Palmer
877-379-3718
Back
to Top |
Location: Columbus
Columbus
CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Deborah A. Halk
614-443-5243
Back
to Top |
Location: Fremont
Fremont
Memorial Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu
Back
to Top |
Location: Maumee
NW Ohio
Oncology Center/ St. Luke's Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Brenda Buczek
419-891-5600
Back
to Top |
Location: Maumee
NW Ohio
Oncology Center/ St. Luke's Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Brenda Buczek
419-891-5600
Back
to Top |
Location: Oregon
St.Charles
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Karen Schultz
419-696-7465
Back
to Top |
Location: Toledo
Trial Title and Description: Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (CONCERT)-
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
Enrollment Status: Recruiting
Study Dates: Start: March 2009
Expected Completion: December 2011
Condition: Alzheimer's disease
Age Eligibility: 50 Years and older
Gender Eligibility: Both
Enrollment Goal: 1050
Clinical Identifier: NCT00829374
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Medivation, Inc.,
Collaborator: Pfizer
Contact Information:
Jennifer Martinez, CRC
419-841-7369
Back to Top |
Location: Toledo
St. Vincent
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Jane Ringlein
419-251-4239
Back
to Top |
Location: Toledo
Toledo Clinic
Inc.
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Michael W. Uscio
419-843-6147
Back
to Top |
Location: Toledo
Toledo
Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Maureen Williams
419-479-8885
Back
to Top |
Location: Toledo
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
|
